Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
ST. LOUIS PARK, Minn., July 10, 2017 -- NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the appointment of Andrew ElBardissi, M.D. to its Board of Directors, effective immediately. Dr. ElBardissi is replacing Avi Kometz, MD as the representative from Deerfield Management on the NeoChord Board of Directors.
“We are pleased to add Andrew to our Board of Directors, and we look forward to his strategic guidance. With his experience in early stage medical technology development, cardiothoracic surgery and research, Andrew will be of great benefit to the company as we continue progress with our US clinical trial,” said David Chung, President and Chief Executive Officer. “Avi has been an integral part of NeoChord over the past few years, and we are thankful for his partnership and many contributions.”
“I am delighted to join an organization leading the way in minimally invasive treatment of structural heart disease,” said Andrew ElBardissi, “I am looking forward to providing guidance as a member of the Board of Directors as the company continues to excel with their world class clinical, commercial and R&D programs."
Dr. ElBardissi has significant investment experience in the healthcare sector. He is currently an investor on the Private Transactions team at Deerfield Management Company and has previously held roles as an early stage life-sciences venture investor and investment banker. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer reviewed scientific journals and as presented his research at numerous medical and surgical conferences.
About NeoChord, Inc.
Founded in 2007 and based in St. Louis Park, Minnesota, NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair for DMR. NeoChord’s DS1000 system received CE market clearance in December 2012. NeoChord received IDE approval from the FDA for the US pivotal trial in May 2016. For more information, please visit the Company's website at www.neochord.com.
The NeoChord DS1000 System is CE marked and approved for sale in Europe.
CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use.
NEOCHORD, DS1000, RECHORD, the stylized logos, and Transforming Mitral Valve Repair are registered trademarks or service marks of the NeoChord Corporation.
Contact: Bruce Van Deman NeoChord, Inc. (952) 698-7812 or (949) 413-1301 [email protected]
